Recent Finacing
Recent Raise
Atriva Therapeutics develops ATR-002, an oral MEK inhibitor antiviral that blocks MEK/ERK signaling to inhibit replication and modulate inflammation in respiratory RNA viruses; Phase I complete, Phase II initiated.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
